kr483.00
0.42% today
Copenhagen, Oct 15, 04:59 pm CET
ISIN
DK0060257814
Symbol
ZEAL

Zealand Pharma Stock price

kr483.00
+54.30 12.67% 1M
+38.00 8.54% 6M
-232.50 32.49% YTD
-304.50 38.67% 1Y
+306.70 173.96% 3Y
+225.80 87.79% 5Y
+325.00 205.70% 10Y
+397.00 461.63% 20Y
Copenhagen, Closing price Wed, Oct 15 2025
+2.00 0.42%
ISIN
DK0060257814
Symbol
ZEAL
Industry

Key metrics

Basic
Market capitalization
kr36.2b
Enterprise Value
kr20.1b
Net debt
positive
Cash
kr16.6b
Shares outstanding
70.4m
Valuation (TTM | estimate)
P/E
5.2 | 5.5
P/S
4.0 | 3.8
EV/Sales
2.2 | 2.1
EV/FCF
2.7
P/B
2.3
Financial Health
Equity Ratio
90.7%
Return on Equity
-12.5%
ROCE
46.0%
ROIC
-1,345.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
kr9.1b | kr9.6b
EBITDA
kr7.4b | kr7.2b
EBIT
kr7.4b | kr7.1b
Net Income
kr6.7b | kr6.2b
Free Cash Flow
kr7.5b
Growth (TTM | estimate)
Revenue
2,375.7% | 15,152.8%
EBITDA
1,168.0% | 682.5%
EBIT
1,108.5% | 661.4%
Net Income
1,038.3% | 671.6%
Free Cash Flow
1,498.8%
Margin (TTM | estimate)
Gross
100.1%
EBITDA
81.3% | 75.7%
EBIT
81.0%
Net
73.3% | 64.5%
Free Cash Flow
82.6%
More
EPS
kr93.2
FCF per Share
kr106.9
Short interest
-
Employees
335
Rev per Employee
kr190.0k
Show more

Is Zealand Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Zealand Pharma Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Zealand Pharma forecast:

21x Buy
88%
3x Hold
13%

Analyst Opinions

24 Analysts have issued a Zealand Pharma forecast:

Buy
88%
Hold
13%

Financial data from Zealand Pharma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
9,110 9,110
2,376% 2,376%
100%
- Direct Costs -5.40 -5.40
116% 116%
0%
9,115 9,115
2,623% 2,623%
100%
- Selling and Administrative Expenses 461 461
73% 73%
5%
- Research and Development Expense 1,272 1,272
61% 61%
14%
7,404 7,404
1,168% 1,168%
81%
- Depreciation and Amortization 25 25
36% 36%
0%
EBIT (Operating Income) EBIT 7,379 7,379
1,108% 1,108%
81%
Net Profit 6,681 6,681
1,038% 1,038%
73%

In millions DKK.

Don't miss a Thing! We will send you all news about Zealand Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.

Head office Denmark
CEO Adam Steensberg
Employees 335
Founded 1997
Website www.zealandpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today